Search Results - "BEASLEY, Georgia M"

Viral infection of cells within the tumor microenvironment mediates antitumor immunotherapy via selective TBK1-IRF3 signaling by Brown, Michael C., Mosaheb, Mubeen M., Mohme, Malte, McKay, Zachary P., Holl, Eda K., Kastan, Jonathan P., Yang, Yuanfan, Beasley, Georgia M., Hwang, E. Shelley, Ashley, David M., Bigner, Darell D., Nair, Smita K., Gromeier, Matthias

“…Activating intra-tumor innate immunity might enhance tumor immune surveillance. Virotherapy is proposed to achieve tumor cell killing, while indirectly…”
Get full text

Pharmacological Wnt ligand inhibition overcomes key tumor-mediated resistance pathways to anti-PD-1 immunotherapy by DeVito, Nicholas C., Sturdivant, Michael, Thievanthiran, Balamayooran, Xiao, Christine, Plebanek, Michael P., Salama, April K.S., Beasley, Georgia M., Holtzhausen, Alisha, Novotny-Diermayr, Veronica, Strickler, John H., Hanks, Brent A.

“…While immune checkpoint blockade is associated with prolonged responses in multiple cancers, most patients still do not benefit from this therapeutic strategy…”
Get full text

Examining Peripheral and Tumor Cellular Immunome in Patients With Cancer by Holl, Eda K, Frazier, Victoria N, Landa, Karenia, Beasley, Georgia M, Hwang, E Shelley, Nair, Smita K

“…Immunotherapies are rapidly being integrated into standard of care (SOC) therapy in conjunction with surgery, chemotherapy, and radiotherapy for many cancers…”
Get full text

Melanoma lymph node metastases - moving beyond quantity in clinical trial design and contemporary practice by Rhodin, Kristen E, Fimbres, Denisse Porras, Burner, Danielle N, Hollander, Shayna, O'Connor, Margaret H, Beasley, Georgia M

“…The presence of lymph node metastases is a well-studied prognostic factor for cutaneous melanoma. Characterization of melanoma lymph node metastases and their…”
Get full text

Phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma by Beasley, Georgia M, Nair, Smita K, Farrow, Norma E, Landa, Karenia, Selim, Maria Angelica, Wiggs, Carol Ann, Jung, Sin-Ho, Bigner, Darell D, True Kelly, Andrea, Gromeier, Matthias, Salama, April KS

“…BackgroundWhile programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) antagonists have improved the prognosis for many patients with…”
Get full text

Surveillance strategies in the follow-up of melanoma patients: too much or not enough? by Kurtz, James, MD, Beasley, Georgia M., MD, Agnese, Doreen, MD, Kendra, Kari, MD, PhD, Olencki, Thomas E., DO, Terando, Alicia, MD, Howard, J. Harrison, MD

“…Abstract Background After appropriate initial therapy for patients with stage II-III melanoma, there is no consensus regarding surveillance. Thus, follow-up is…”
Get full text

Oncolytic viruses in melanoma by Robinson, Camille, Xu, Maria M, Nair, Smita K, Beasley, Georgia M, Rhodin, Kristen E

“…Malignant melanoma recurrence remains heterogeneous in presentation, ranging from locoregional disease (i.e., local recurrence, satellites, in transit disease)…”
Get full text

Functional reprogramming of peripheral blood monocytes by soluble mediators in patients with pancreatic cancer and intraductal papillary mucinous neoplasms by Eckhoff, Austin M, Brown, Michael C, Landa, Karenia, Naqvi, Ibtehaj, Holl, Eda K, Boczkowski, David, Fletcher, Ashley, Rhodin, Kristen E, Giang, Minh Huy, Sullenger, Bruce, Beasley, Georgia M, Allen, Peter J, Nair, Smita K

“…Monocytes and monocyte-derived tumor infiltrating cells have been implicated in the immunosuppression and immune evasion associated with pancreatic…”
Get full text

Spatial biology analysis reveals B cell follicles in secondary lymphoid structures may regulate anti-tumor responses at initial melanoma diagnosis by Therien, Aaron D, Beasley, Georgia M, Rhodin, Kristen E, Farrow, Norma E, Tyler, Douglas S, Boczkowski, David, Al-Rohil, Rami N, Holl, Eda K, Nair, Smita K

“…B cells are key regulators of immune responses in melanoma. We aimed to explore differences in the histologic location and activation status of B cell…”
Get full text

Prospective Multicenter Phase II Trial of Systemic ADH-1 in Combination With Melphalan via Isolated Limb Infusion in Patients With Advanced Extremity Melanoma by BEASLEY, Georgia M, RIBOH, Jonathan C, AUGUSTINE, Christina K, ZAGER, Jonathan S, HOCHWALD, Steven N, GROBMYER, Stephen R, PETERSON, Bercedis, ROYAL, Richard, ROSS, Merrick I, TYLER, Douglas S

“…Isolated limb infusion (ILI) with melphalan (M-ILI) dosing corrected for ideal body weight (IBW) is a well-tolerated treatment for patients with in-transit…”
Get full text

Predictive factors of neoadjuvant immune checkpoint blockade in melanoma by Sarver, Melissa, Brown, Michael C., Rhodin, Kristen E., Salama, April K. S., Beasley, Georgia M.

“…This review describes the current body of literature and ongoing clinical trials examining neoadjuvant immune checkpoint inhibitors (ICI) for patients with…”
Get full text

Current Trends in Regional Therapy for Melanoma: Lessons Learned from 225 Regional Chemotherapy Treatments between 1995 and 2010 at a Single Institution by Raymond, Amanda K., BS, Beasley, Georgia M., MD, Broadwater, Gloria, MS, Augustine, Christina K., PhD, Padussis, James C., MD, Turley, Ryan, MD, Peterson, Bercedis, PhD, Seigler, Hilliard, MD, FACS, Pruitt, Scott K., MD, PhD, FACS, Tyler, Douglas S., MD, FACS

“…Background Hyperthermic isolated limb perfusion (HILP) and isolated limb infusion (ILI) are used to manage advanced extremity melanoma, but no consensus exists…”
Get full text

Intratumor childhood vaccine-specific CD4+ T-cell recall coordinates antitumor CD8+ T cells and eosinophils by Brown, Michael C, Beasley, Georgia M, McKay, Zachary P, Yang, Yuanfan, Desjardins, Annick, Randazzo, Dina M, Landi, Daniel, Ashley, David M, Bigner, Darell D, Nair, Smita K, Gromeier, Matthias

“…BackgroundAntitumor mechanisms of CD4+ T cells remain crudely defined, and means to effectively harness CD4+ T-cell help for cancer immunotherapy are lacking…”
Get full text

Efficacy of Repeat Sentinel Lymph Node Biopsy in Patients Who Develop Recurrent Melanoma by Beasley, Georgia M., MD, Speicher, Paul, MD, Sharma, Ketan, MD, Seigler, Hilliard, MD, FACS, Salama, April, MD, Mosca, Paul, MD, PhD, FACS, Tyler, Douglas S., MD, FACS

“…Background Even after negative sentinel lymph node biopsy (SLNB) for primary melanoma, patients who develop in-transit (IT) melanoma or local recurrences (LR)…”
Get full text

Bevacizumab-Induced Alterations in Vascular Permeability and Drug Delivery: A Novel Approach to Augment Regional Chemotherapy for In-Transit Melanoma by TURLEY, Ryan S, FONTANELLA, Andrew N, TYLER, Douglas S, PADUSSIS, James C, TOSHIMITSU, Hiroaki, TOKUHISA, Yoshihiro, CHO, Eugenia H, HANNA, Gabi, BEASLEY, Georgia M, AUGUSTINE, Christina K, DEWHIRST, Mark W

“…To investigate whether the systemically administered anti-VEGF monoclonal antibody bevacizumab could improve regional chemotherapy treatment of advanced…”
Get full text

Multimodality analysis confers a prognostic benefit of a T-cell infiltrated tumor microenvironment and peripheral immune status in patients with melanoma by Beasley, Georgia M, Brown, Michael C, Farrow, Norma E, Landa, Karenia, Al-Rohil, Rami N, Selim, Maria Angelica, Therien, Aaron D, Jung, Sin-Ho, Gao, Junheng, Boczkowski, David, Holl, Eda K, Salama, April K S, Bigner, Darell D, Gromeier, Matthias, Nair, Smita K

“…BackgroundWe previously reported results from a phase 1 study testing intratumoral recombinant poliovirus, lerapolturev, in 12 melanoma patients. All 12…”
Get full text

A Multi-Institutional Experience of Isolated Limb Infusion: Defining Response and Toxicity in the US by Beasley, Georgia M., MD, Caudle, Abigail, MD, Petersen, Rebecca P., MD, BS, McMahon, Nicole S., BS, Padussis, James, MD, Mosca, Paul J., MD, PhD, FACS, Zager, Jonathan S., MD, FACS, Hochwald, Steven N., MD, FACS, Grobmyer, Stephen R., MD, FACS, Delman, Keith A., MD, Andtbacka, Robert H., MD, Noyes, R. Dirk, MD, FACS, Kane, John M., MD, FACS, Seigler, Hilliard, MD, Pruitt, Scott K., MD, PhD, FACS, Ross, Merrick I., MD, FACS, Tyler, Douglas S., MD, FACS

“…Background Isolated limb infusion (ILI) is a minimally invasive approach for treating in-transit extremity melanoma, with only two US single-center studies…”
Get full text

Acral Lentiginous Melanoma: A United States Multi-Center Substage Survival Analysis by Kolla, Avani M., Vitiello, Gerardo A., Friedman, Erica B., Sun, James, Potdar, Aishwarya, Daou, Hala, Farrow, Norma E., Farley, Clara R., Vetto, John T., Han, Dale, Tariq, Marvi, Beasley, Georgia M, Contreras, Carlo M., Lowe, Michael, Zager, Jonathan S., Osman, Iman, Berman, Russell S., Liebman, Tracey N., Stein, Jennifer A., Lee, Ann Y.

“…Background Acral lentiginous melanoma is associated with worse survival than other subtypes of melanoma. Understanding prognostic factors for survival and…”
Get full text

Type of Organ Transplanted Impacts the Risk and Presentation of Cutaneous Squamous Cell Carcinoma in Transplant Recipients by Puza, Charles J., Beasley, Georgia M., Barbas, Andrew S., Mosca, Paul J.

“…Objectives: Transplant immunosuppression increases the risk of cutaneous squamous cell carcinoma by 65- to 200-fold. Our objective was to investigate the…”
Get full text

Overall Survival Improved for Contemporary Patients with Melanoma: A 2004–2015 National Cancer Database Analysis by Farrow, Norma E., Turner, Megan C., Salama, April K. S., Beasley, Georgia M.

“…Introduction Since 2011, encouraging clinical trial results have led to approval of multiple new therapies for advanced melanoma, but the impact of these…”
Get full text